# Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients

> **NCT02755844** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** metformin
- **DRUG:** metronomic cyclophosphamide

## Key facts

- **NCT ID:** NCT02755844
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-23
- **Primary completion:** 2018-11
- **Final completion:** 2020-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02755844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02755844, "Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02755844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*